Previous 10 | Next 10 |
Aquestive Therapeutics, Inc. (AQST) Q3 2019 Earnings Conference Call November 06, 2019 08:00 AM ET Company Participants Stephanie Carrington - Westwicke Investor Relations Keith Kendall - Chief Executive Officer John Maxwell - Chief Financial Officer Ken Marshall - Chief Commer...
Gainers: Constellation Pharmaceuticals (NASDAQ: CNST ) +99% . More news on: Constellation Pharmaceuticals, Inc., FuelCell Energy, Inc., comScore, Inc., Stocks on the move, Read more ...
Thinly traded micro cap Aquestive Therapeutics ( AQST +18.2% ) is up on more than a 7x surge in volume, albeit on turnover of only 790K shares, in reaction to its Q3 report that included a guidance raise. Highlights: More news on: Aquestive Therapeutics, Inc., Healthcare stocks ne...
Aquestive Therapeutics (NASDAQ: AQST ): Q3 GAAP EPS of -$0.74 misses by $0.04 . More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Increases full year 2019 revenue and earnings guidance Expects to complete its rolling New Drug Application (NDA) submission for Libervant™ (diazepam) Buccal Film around the end of November 2019 Reported successful completion of its Phase 1 dose escalation proof-of-concept study i...
Gainers: Tiffany & Co. (NYSE: TIF ) +31% . Xunlei Limited (NASDAQ: XNET ) +27% . Datasea (NASDAQ: DTSS ) +25% . comScore (NASDAQ: SCOR ) +24% . Fitbit (NYSE: FIT ) +23% . Aquestive Therapeutics (NASDAQ: AQST ) +23% . ChinaNet Online Holdings (NASDAQ: CNET ) +20% . Libbey (...
WARREN, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST ), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced, in response to Indivior PLC’s press rele...
Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test of the top three forensic algorithms used to detect bankruptcy risk, earnings manipulation, and financial irregularities. My forward testing compiles portfolio ...
When you are being judged by someone that has no idea who you are always remember this: Dogs always bark at strangers and usually there is always some wacko neighbor that wants to try out their new gun on an intruder ." - Shannon L. Alder Today, we look at a deeply 'Busted IPO' that just ...
Aquestive Therapeutics (NASDAQ: AQST ) has completed its Phase 1 dose escalation proof-of-concept study in healthy subjects for AQST-108. More news on: Aquestive Therapeutics, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...